ATE512133T1 - 1h-pyrrol-2-carbonsäureamide und imidazol-5- carbonsäureamide und deren verwendung als fak-, kdr- und tie2-kinase-modulatoren zur behandlung von krebs - Google Patents

1h-pyrrol-2-carbonsäureamide und imidazol-5- carbonsäureamide und deren verwendung als fak-, kdr- und tie2-kinase-modulatoren zur behandlung von krebs

Info

Publication number
ATE512133T1
ATE512133T1 AT06709213T AT06709213T ATE512133T1 AT E512133 T1 ATE512133 T1 AT E512133T1 AT 06709213 T AT06709213 T AT 06709213T AT 06709213 T AT06709213 T AT 06709213T AT E512133 T1 ATE512133 T1 AT E512133T1
Authority
AT
Austria
Prior art keywords
carbonic acid
acid amides
fak
kdr
pyrrole
Prior art date
Application number
AT06709213T
Other languages
English (en)
Inventor
Baptiste Ronan
Frank Halley
Catherine Souaille
Fabrice Viviani
Youssef El-Ahmad
Eric Bacque
Michel Tabart
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE512133T1 publication Critical patent/ATE512133T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
AT06709213T 2005-02-03 2006-02-01 1h-pyrrol-2-carbonsäureamide und imidazol-5- carbonsäureamide und deren verwendung als fak-, kdr- und tie2-kinase-modulatoren zur behandlung von krebs ATE512133T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0501092A FR2881426B1 (fr) 2005-02-03 2005-02-03 Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation
PCT/FR2006/000220 WO2006082309A1 (fr) 2005-02-03 2006-02-01 l-H-PYROLE-2-CARBOXAMIDES ET IMIDAZOLE-5-CARBOXAMIDES ET LEUR UTILISATION EN TANT MODULATEURS DES KINASES FAK, KDR ET TIE2 POUR TRAITER LE CANCER

Publications (1)

Publication Number Publication Date
ATE512133T1 true ATE512133T1 (de) 2011-06-15

Family

ID=34954950

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06709213T ATE512133T1 (de) 2005-02-03 2006-02-01 1h-pyrrol-2-carbonsäureamide und imidazol-5- carbonsäureamide und deren verwendung als fak-, kdr- und tie2-kinase-modulatoren zur behandlung von krebs

Country Status (20)

Country Link
US (1) US7560571B2 (de)
EP (1) EP1856043B1 (de)
JP (1) JP2008528661A (de)
KR (1) KR20070103420A (de)
CN (1) CN101133023A (de)
AR (1) AR053540A1 (de)
AT (1) ATE512133T1 (de)
AU (1) AU2006210343A1 (de)
BR (1) BRPI0606761A2 (de)
CA (1) CA2595987A1 (de)
EA (1) EA012267B1 (de)
FR (1) FR2881426B1 (de)
IL (1) IL184710A0 (de)
MA (1) MA29264B1 (de)
MX (1) MX2007009442A (de)
NO (1) NO20074414L (de)
TW (1) TW200640857A (de)
UY (1) UY29361A1 (de)
WO (1) WO2006082309A1 (de)
ZA (1) ZA200706338B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2881742B1 (fr) 2005-02-10 2007-09-07 Aventis Pharma Sa Pyrroles substitues, compositions les contenant, procede de fabrication et utilisation
US7589214B2 (en) 2006-04-11 2009-09-15 Vertex Pharmaceuticals Incorporated Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
DK2318007T3 (da) 2008-08-15 2013-03-25 N30 Pharmaceuticals Inc Nye pyrrol-inhibitorer af s-nitrosoglutathion-reduktase som terapeutiske midler
HUE031580T2 (en) 2008-08-15 2017-07-28 Nivalis Therapeutics Inc Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
EP2315590B1 (de) 2008-08-15 2012-09-26 N30 Pharmaceuticals, LLC Pyrrolhemmer der s-nitrosoglutathion-reduktase
CN102775354A (zh) * 2011-05-10 2012-11-14 无锡立诺康医药科技有限公司 一种合成4-芳基-5-羧酸咪唑及其酯的工艺方法
MA37830B1 (fr) 2012-08-10 2018-09-28 Boehringer Ingelheim Int Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk)
US9828364B2 (en) 2014-01-29 2017-11-28 Boehringer Ingelheim International Gmbh Pyrazole compounds as BTK inhibitors
PE20181074A1 (es) 2015-12-16 2018-07-04 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de btk
US10570118B2 (en) 2016-01-13 2020-02-25 Boehringer Ingelheim International Gmbh Isoquinolones as BTK inhibitors
EP3886854A4 (de) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrol- und pyrazolverbindungen und verfahren zu deren verwendung
CN119528787A (zh) * 2023-08-31 2025-02-28 上海柏狮生物科技有限公司 以异腈和Michael受体制备一系列沃诺拉赞中间体的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020173507A1 (en) * 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
GB0107901D0 (en) * 2001-03-29 2001-05-23 Cyclacel Ltd Anti-cancer compounds
EP1436265A4 (de) * 2001-09-27 2004-12-15 Smithkline Beecham Corp Chemische verbindungen
US20040138269A1 (en) * 2002-10-11 2004-07-15 Sugen, Inc. Substituted pyrroles as kinase inhibitors
EP1633709A1 (de) * 2003-04-30 2006-03-15 Pfizer Products Inc. Verbindungen zur verwendung als anti-diabetika
DE10354060A1 (de) * 2003-11-19 2005-06-02 Merck Patent Gmbh Pyrrolderivate
US7183285B2 (en) * 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
FR2881742B1 (fr) 2005-02-10 2007-09-07 Aventis Pharma Sa Pyrroles substitues, compositions les contenant, procede de fabrication et utilisation

Also Published As

Publication number Publication date
ZA200706338B (en) 2008-11-26
KR20070103420A (ko) 2007-10-23
BRPI0606761A2 (pt) 2009-07-14
AR053540A1 (es) 2007-05-09
WO2006082309A1 (fr) 2006-08-10
EP1856043A1 (de) 2007-11-21
FR2881426A1 (fr) 2006-08-04
UY29361A1 (es) 2006-08-31
AU2006210343A1 (en) 2006-08-10
IL184710A0 (en) 2007-12-03
EA012267B1 (ru) 2009-08-28
TW200640857A (en) 2006-12-01
US7560571B2 (en) 2009-07-14
US20080045542A1 (en) 2008-02-21
CA2595987A1 (fr) 2006-08-10
MX2007009442A (es) 2008-03-10
CN101133023A (zh) 2008-02-27
MA29264B1 (fr) 2008-02-01
FR2881426B1 (fr) 2007-03-30
JP2008528661A (ja) 2008-07-31
EA200701648A1 (ru) 2008-02-28
NO20074414L (no) 2007-11-05
EP1856043B1 (de) 2011-06-08

Similar Documents

Publication Publication Date Title
EP1765391A4 (de) Bakterielle zusammensetzungen zur behandlung von krebs
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
DE602008002843D1 (de) Neue antimikrobielle verbindungen, ihre synthese und ihre verwendung zur behandlung von säugetierinfektionen
IL184710A0 (en) 1-h-pyrrole-2-carboxamides and imidazole-5-carboxamides and use thereof as fak, kdr and tie2 kinase modulators for the treatment of cancer
ATE447559T1 (de) 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen
EP1484366A4 (de) Behandeltes pigment, dessen verwendung und verbindung zur behandlung von pigmenten
ATE532507T1 (de) Neramexane zur behandlung von subakuten tinnitus
ATE481984T1 (de) Vakzine-peptid-kombinationen gegen katzenallergie
DE602006006354D1 (de) Pinolensäure zur Behandlung von Übergewicht
EP1934025A4 (de) Zusammensetzung zur behandlung von holz, verfahren zur behandlung von holz und holzprodukt
ATE447570T1 (de) Pyrimidinderivate zur verwendung als vanilloidrezeptorliganden und deren verwendung bei der behandlung von schmerzen
DE602007011906D1 (de) Tetrahydropyridothienpyrimidin-verbindungen und verwendung zur behandlung proliferativer erkrankungen
ATE525372T1 (de) Pyrazinderivate als natriumkanalmodulatoren zur behandlung von schmerzen
DE602005017503D1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE521365T1 (de) Kinin-antagonisten zur behandlung von blasenfunktionsstörung
DE602004021435D1 (de) Injizierbare zusammensetzung zur behandlung von krebs
EP2340039A4 (de) Verwendung von il-20-antagonisten zur behandlung von rheumatioder arthritis und osteoporose
EP1863520A4 (de) Verwendung von interleukin 17e zur behandlung von krebs
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken
EP2029172A4 (de) Antikörper gegen c35 zur behandlung von krebs
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
ATE428712T1 (de) 4-amino-5-oxo-8-phenyl-5h-pyrido-ä2,3-dü- pyrimidin-derivate als inhibitoren der tyrosinkinasen und der raf-kinasen zur behandlung von tumoren
ATE503481T1 (de) Verwendung von 4-cyclopropylmethoxy-n-(3,5- dichlor-1-oxidopyridin-4-yl)-5-(methoxy)-pyridi - 2-carboxamid zur behandlung von rückenmarksverletzungen
ATE458481T1 (de) Kombination von phenylcarbonsäureamiden mit blockern des ikr-kanals und deren verwendung zur behandlung von vorhofarrhythmien
DE602006007542D1 (de) Einheit zur sterilisierung und depyrogenierung von containern

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties